Article
Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jun 2008
Byrd Louise M, Shenton Andrew, Maher Eamonn R, Woodward Emma, Belk Rachel, Lim Caron, Lalloo Fiona, Howell Anthony, Jayson Gordon C, Evans Gareth D
Abstract excerpt
PURPOSE: No formal assessment of life expectancy in women with BRCA1 and BRCA2 mutations in these genes has been reported previously. We have evaluated life expectancy using actuarial analysis and assessed the effect of breast and ovarian cancers on premature death in >1,000 BRCA1/2 carriers. METHODS: Families with pathogenic mutations in BRCA1 and BRCA2 have been ascertained in a 10-million population region of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.